Ulcerative Colitis Market Analysis | 2022-2028

Ulcerative Colitis Market Analysis | 2022-2028

Ulcerative Colitis Market Analysis | 2022-2028
Report code - SR2198 Delivery - 2 Weeks
Ulcerative Colitis Market Size, Share, Trend, Forecast, Competitive Analysis, and Growth O See more...

“The Ulcerative Colitis Market was estimated at US$ 6.6 billion in 2021 and is expected to grow at a CAGR of 5.8% during 2022-2028 to reach US$ 10.9 billion in 2028”.

Wish to get a free sample? Register Here

Market Dynamics

Introduction

Inflammation and ulcers on the inner lining of the large intestine are symptoms of the chronic inflammatory bowel disease (IBD) known as ulcerative colitis. Ulcerative colitis typically starts in the rectum and can extend continuously to affect other parts of the colon. The exact cause remains unclear, but it's believed to involve an overactive immune response triggered by genetic and environmental factors.

Market Drivers

Globally increasing rates of ulcerative colitis are promoting market expansion. The market is expanding as a result of rising investment in research & development capabilities to create novel treatments. Growing efforts by governmental and non-governmental organizations to conduct biologics research are also boosting the market for ulcerative colitis treatments.

According to Arizton's prediction, the United States had the highest rate of inflammatory bowel disease incident cases in 2020, followed by China and the UK. The market for ulcerative colitis medications is expanding as the disease becomes more common. In the US, one million people were estimated to have inflammatory bowel illness in 2019.

More than 155 trials in various stages of development are included in the clinical trial portfolio. Most industry-sponsored medications for inflammatory bowel disease in active clinical research are in Phase II, with three medications at the NDA/BLA stage. With 84% of studies in Phase I-II and only 16% in Phase III-IV, the distribution of clinical trials across Phase I-IV shows that the bulk of trials for ulcerative colitis have been in the primary and mid stages of development. Worldwide, the US has a substantial advantage in clinical studies for ulcerative colitis.

With certain restrictions, most drugs for UC are covered by both pharmacy and medical benefits. For all medications, more than half of the covered lives are enrolled in the pharmacy benefit's preferred tier, preferred with prior authorization, or step therapy, and covered tier, covered with PA/ST. The Entyvio Patient Assistance Programs provide product assistance to qualified patients who have been given a UC diagnosis. Through aid with co-pays, nurse support, and helpful advice, this initiative aims to benefit patients. EntyvioConnect may assist patients who have been prescribed the drug at every stage of the insurance approval procedure and works directly with eligible individuals to make sure they can afford the medication.

The complex course of treatment for UC includes the administration of medications, dietary and nutritional changes, and occasionally, surgical operations to reconstruct or remove the patient's GI tract. Aminosalicylates, corticosteroids, immunomodulators, biological treatments, and Janus kinase (JAK) inhibitors are some of the drugs being used for treatment. Combination therapies and dietary supplements are occasionally also advised.

Surgery is recommended as the best alternative if the patient is no longer responding to medicine if it is not working as well as it once did, or if the patient experiences frequent flare-ups. Anti-inflammatory pharmaceuticals with 5-aminosalicylic acid, including mesalazine sulfasalazine and olsalazine, are some of the regularly used medications for treating ulcerative colitis. Although corticosteroid drugs like budesonide and prednisone are also employed, they are often not given over an extended period of time due to their negative effects. If the illness is located in the colon, antibiotics may be recommended. Furthermore, a key aspect of the medications' successful positioning on the market is consumer awareness of ulcerative colitis treatment.

Several investments/guidelines in the industry have been directed in recent years, which would boost the overall market. Some of them are:

  • In 2022, the USFDA approved the use of small molecules to treat moderate-to-severe ulcerative colitis, including Jyseleca (Filgotinib) and Rinvoq (Upadacitinib). The market for ulcerative colitis treatments will experience significant expansion as a result of the introduction of authorized small molecules and the continued adoption of biological therapies.
  • The market under study has shown significant expansion, which is attributable to the rising incidence of inflammatory bowel disease across the globe. In 2018, there were 910,000 cases of inflammatory bowel disease in the United States, according to estimates.

Recent Developments

The market for ulcerative colitis is highly competitive. The state of the economy and government assistance have a direct impact on the expansion of businesses. Based on their product's quality and market penetration in both the target and growing markets, these companies distinguish their ulcerative colitis driver in the industry. Furthermore, recent important mergers and acquisitions in the sector have had a big impact on the dynamics of competition. For instance:

  • In 2022, the US FDA approved small molecules, namely, Jyseleca (Filgotinib) and Rinvoq (Upadacitinib) to treat moderate to severe cases of ulcerative colitis.
  • In October 2022, The National Institute for Health and Care Excellence (NICE) has recommended Bristol Myers Squibb's (BMS) Zeposia (ozanimod) for the treatment of adults with moderate-to-severe active ulcerative colitis (UC). This is the first time that NICE has recommended an oral sphingosine 1-phosphate (S1P) receptor modulator for the treatment of UC. The advice is specifically for individuals whose conditions have not responded well to earlier biologic therapy or conventional therapy, or who are intolerant of it.
  • In July 2021, Bristol Myers Squibb reported that neither the primary efficacy endpoint of clinical remission at Week 12 nor the secondary efficacy endpoints were met in the Phase 2 LATTICE-UC study comparing deucravacitinib, a first-in-class oral selective tyrosine kinase 2 (TYK2) inhibitor, to placebo in patients with moderate to severe ulcerative colitis (UC). Deucravacitinib's safety profile was similar to trials on psoriasis and psoriatic arthritis that have already been published, and no new safety signals were noticed.

Segments Analysis

Segmentations

List of Sub-Segments

Dominant and Fastest-Growing Segments

Disease-Type Analysis

Mild, Moderate, and Severe

The moderate segment is expected to grow the highest over the anticipated period.

Molecule-Type Analysis

Biologics, and Small Molecules

The biologics segment is expected to hold the major share owing to the high awareness.

Regional Analysis

North America, Europe, Asia-Pacific, and Rest of the World

North America is anticipated to be the ulcerative colitis market's largest region in 2021.

 

By Disease Type

“The moderate segment is expected to grow the highest over the anticipated period”.

The market is further segmented into mild, moderate, and severe. The moderate segment is expected to grow the highest over the anticipated period.

By Molecule Type

“The biologics segment is expected to hold the major share owing to the high awareness”.

The ulcerative colitis market has been divided into biologics and small molecules. The biologics segment is expected to hold the major share owing to the high awareness.

Regional Analysis

“North America is anticipated to be the ulcerative colitis market's largest region”.

The ulcerative colitis market is broken down geographically into areas like North America, Europe, Asia-Pacific, and the Rest of the World (RoW). In 2021, North America is anticipated to be the ulcerative colitis market's largest region. Due to improved healthcare costs, more public understanding and awareness, and technological innovation in the US, this country dominates the ulcerative colitis market.

However, the UK is anticipated to grow more quickly and with a high CAGR in the ulcerative colitis drug market due to improvements in healthcare access and quality, a rise in disease management knowledge, and rising healthcare spending in this area. The popularity of biosimilars in developing nations like China and Japan may change the therapeutic environment here.

Want to know which region offers the best growth opportunities? Register Here

Key Players

The following are the major players in the Ulcerative Colitis Market (arranged alphabetically)

  • AbbVie Inc
  • Bristol-Myers Squibb
  • CellTrion
  • EA Pharma
  • Eli Lilly and Company
  • InDex
  • Johnson & Johnson
  • Pfizer Inc 
  • Reistone Biopharma Co. Ltd.
  • Takeda Pharmaceutical Co Ltd.

The overall competitive landscape has been affected due to these mergers and acquisitions. 

Note: The above list does not necessarily include all the top players in the market.

Are you the leading player in this market? We would love to include your name. Write to us at sales@stratviewresearch.com

Report Features

This report provides market intelligence in the most comprehensive way. The report structure has been kept such that it offers maximum business value. It provides critical insights into the market dynamics and will enable strategic decision-making for the existing market players as well as those willing to enter the market.

What Deliverables Will You Get in this Report?

Key questions this report answers

Relevant contents in the report

How big is the sales opportunity?

in-depth Analysis of the Ulcerative Colitis Market

How lucrative is the future?

The market forecast and trend data and emerging trends

Which regions offer the best sales opportunities?

Global, regional, and country-level historical data and forecasts

Which are the most attractive market segments?

Market segment analysis and Forecast

Which are the top players and their market positioning?

Competitive landscape analysis, Market share analysis

How complex is the business environment?

Porter’s five forces analysis, PEST analysis, Life cycle analysis

What are the factors affecting the market?

Drivers & challenges

Will I get the information on my specific requirement?

10% free customization

Research Methodology

This report offers high-quality insights and is the outcome of a detailed research methodology comprising extensive secondary research, rigorous primary interviews with industry stakeholders, and validation and triangulation with Stratview Research’s internal database and statistical tools.

More than 1,000 authenticated secondary sources, such as company annual reports, fact books, press releases, journals, investor presentations, white papers, patents, and articles have been leveraged to gather the data.

We conducted more than 15 detailed primary interviews with the market players across the value chain in all four regions and with industry experts to obtain both qualitative and quantitative insights.

Customization Options

With this detailed report, Stratview Research offers one of the following free customization options to our respectable clients:

Company Profiling

  • Detailed profiling of additional market players (up to three players)
  • SWOT analysis of key players (up to three players)

Competitive Benchmarking

  • Benchmarking of key players on the following parameters: Product portfolio, geographical reach, regional presence, and strategic alliances.

Custom Research:

Stratview research offers custom research services across sectors. In case of any custom research requirement related to market assessment, competitive benchmarking, sourcing and procurement, target screening, and others, please send your inquiry to sales@stratviewresearch.com.

Frequently Asked Questions (FAQs)

Inflammation and ulcers on the inner lining of the large intestine are symptoms of the chronic inflammatory bowel disease (IBD) known as ulcerative colitis.

The ulcerative colitis market is estimated to reach US$ 10.9 billion in 2028.

The ulcerative colitis market is expected to grow at a CAGR of 5.8% during 2022-2028.

Globally increasing rates of ulcerative colitis are promoting market expansion. The market is expanding as a result of rising investment in research & development capabilities to create novel treatments. Growing efforts by governmental and non-governmental organizations to conduct biologics research are also boosting the market for ulcerative colitis treatments.

In 2021, North America is anticipated to be the ulcerative colitis market's largest region. Due to improved healthcare costs, more public understanding and awareness, and technological innovation in the US, this country dominates the ulcerative colitis market.

The major players in the ulcerative colitis market are AbbVie Inc, Bristol-Myers Squibb, CellTrion, EA Pharma, Eli Lilly and Company, InDex, Johnson & Johnson, Pfizer Inc, Reistone Biopharma Co. Ltd., Takeda Pharmaceutical Co Ltd.

The market is studied from 2016-2028.